© 2026 Improve the News Foundation.
All rights reserved.
Version 8.0.0
The longer lecanemab is used, the bigger the payoff, with the gap in decline widening year after year instead of fizzling out. Starting treatment early matters most: 62% of low-tau patients improved on memory and daily living at five years, and the risk of sliding into the next stage fell 36%. Safety held steady too, with swelling events dropping sharply after the first year.
Past decisions by health authorities to block licensed Alzheimer's drugs over cost look increasingly misguided in light of these findings. Denying patients the chance of greater independence is a false economy when it prolongs the burden on families and care systems. Prominent figures like David Cameron are right to demand that NHS-style bodies approve more promising treatments and prioritize long-term patient benefits over short-term cost calculations.
The NHS is right to demand convincing value before committing scarce resources to lecanemab. Any benefits must be weighed against potentially serious side effects, including brain swelling and bleeding, while costly treatment and safety monitoring could divert staff and money from services that help more patients. Protecting access to effective care requires weighing these trade-offs, even when a new drug offers hope.